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Beside general requirements for modern automated systems,
immunoassay automation involves specific requirements as a
separation step for heterogeneous immunoassays. Systems are
designed according to the solid phase selected: dedicated or open
robots for coated tubes and wells, systems nearly similar to
chemistry analysers in the case of magnetic particles, and a
completely original design for those using porous and film
materials.
Introduction
The field ofimmunoassay has shown enormous growth in
the last two decades and this has led to a need to
automate. The principal advantages of using automated
systems include:
(1) Avoidance of tedious and repetitive manual
procedures.
(2) Control of reaction conditions significantly impro-
ving performance.
(3) Limitation of biohazards.
The automation of the immunological reaction is dis-
cussed under three headings: Heterogeneous versus
homogeneous immunoassays; Constraints in automation
of the immunological reaction; and Automated separ-
ation using different solid phases. The authors then
identify some new trends in this area.
Heterogeneous versus homogeneous immunoassays
In homogeneous immunoassays, antibody binding leads
to a change in the signal, which is measurable from a
label, or from matter in competition for binding with the
substance being measured.
The classical example is EMIT: the enzyme immuno-
assay [1], where the specimen antigen competes with a
labelled conjugate. CEDIA, cloned enzyme donor im-
munoassays, is another example [2].
Immunoprecipitation and immunoagglutination are also
used for the quantitation ofsmall molecules, both directly
and as inhibition processed, with turbidimetric or
nephelometric detection.
In heterogeneous immunoassays, antibody-bound and
free analyte must be separated. The antibody is usually
fixed on a solid phase and other components are usually
added sequentially. Antigens with several binding sites
allow assays in ’sandwich’ form, i.e. a sandwich with the
antigen and a conjugate with an antibody which com-
bines with another epitope of the antigen and the label:
this is an extraction process. This technique also allows
competition between a free antigen and an antigen-
labelled antibody conjugate. In these two cases, the
components which are not bound are eliminated by a
separation step, which usually also involves washing
steps:
The main features of the two kinds of immunological
reactions can be summarized as follows:
(1) The reaction mode: competition for homogeneous
immunoassays, competition and extraction for
heterogeneous immunoassays.
(2) A separation step for heterogeneous immunoassays.
(3) In the homogeneous mode, the modulation of the
signal is measured; in the heterogeneous mode, the
total remaining signal is measured.
(4) With homogeneous immunoassays, it is possible to
determine high concentration analytes with low
molecular weight.
(5) Heterogeneous immunoassays can show similar
sensitivity and imprecision as radioimmunoassays,
with no restriction on molecular size.
Constraints in the automation of the immunological
reaction
In the homogeneous mode, there are only two analytical
steps (reagent addition, incubation and measurement),
which is similar to most chemical assays. Many of these
methods can be adapted to conventional chemistry
analysers.
In the heterogeneous mode, there are many analytical
steps (see table 1). The separation step is a specific
requirement, not found in conventional chemistry ana-
lysers. The constraints to automation are:
(1) Choosing, designing and manufacturing a solid
phase which is equivalent to a reagent.
(2) Reducing the duration of the incubation steps
because if tl and t2 are h, a very large incubator with
more than 300 places will be necessary.
(3) Combining and automating the different components
in a compact automatic system. Such systems are
often based on patented components or analytical
procedures.
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Table 1. Constraints in the automation of heterogeneous
immunoassays.
Analytical steps Constraints
Specimen + reagents , * Choice of a solid phase
Incubation tl
Separation
* tl + t2-+ Capacity of the
/ Reagent incubator
Incubation t2
Measurement * Separation
Automated separation using different solid phases
Only a few analytical systems are well established: there
are several currently being evaluated and developed.
The solid phase is shown in figure with the antibody, the
bound and the solid support. The main solid phases are:
tubes, wells or beads, latex and magnetic particles,
fibrous materials, and, more recently, films.
Coated tubes, wells or beads
The advantages of these classical solid phases for
manufacturers are that immunological reactions and
manufacturing processes are similar to those for radioim-
munoassays; furthermore, the shape and size of the
microtitre plate is a ’standard’, for which robotic
processing is readily available. The drawbacks are a large
physical volume because each analyte needs a specific
coated tube or well, complex mechanical process control
and often long incubation delays. Automation is possible
through dedicated or reprogrammable robots.
A recent improvement in tube technology is to use
’universal’ tubes coated with strepavidin and a biotini-
lated antibody specific to the antigen, then an enzyme
conjugate. This is called the ’soluble sandwich’ approach
[].
To accelerate the reaction by increasing the rate of
immunological events, the size and geometric space in
which the components diffuse can be reduced, the
antibody concentration increased and the solid phase
split into microparticles.
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Figure 1. Solid phases used in immunoassays.
Latex particles
In the Abbott IMX, the latex microparticles of 0"5 bt size
react with the specimen antigen, then with the enzyme
conjugate; the reaction mixture is transferred in a glass
fibre filter where latex particles are captured and then
washed [4]. On addition of a fluorescence generating
substrate, it is possible to quantitate the immuno-
complexes.
Magnetic particles
Magnetic particles seem very attractive, because, at first
sight, the separation process is simple. In fact, magnetic
particles are ’high tech’ products with very precise
requirements:
(1) Limited non-specifi: binding.
(2) Stability of the suspension of these particles.
(3) Avoidance of capturing residual liquid during the
separation process (’entrapment’).
(4) Delay for resuspension.
(5) Avoidance of loss of particles during washing.
It is possible to meter and deliver the suspension in
optical cuvettes of a system very similar to a chemistry
analyser, except that magnets are located near the
cuvettes [5]. The cuvettes are moved in front of the
magnets and the separation and washing steps are
performed when particles are held in place by the
magnets.
It is also possible to measure an absorbance when the
magnetic particles are fixed.
Fibrous andfilm materials
It is possible to fix antibodies on fibrous and film
materials. The immunological events are induced by
moving the other components by diffusion through the
solid in a standardized physical process.
A first approach is to use radial diffusion through a
porous material (for example the Baxter Stratus system).
The unbound reagents are eliminated on the periphery,
the bound immunological complexes stay in the centre
[6]. The automation is performed with a conveyor belt
moving the slides under different dispensers and the
fluorimeter, in a temperature-controlled area.
In the Opus system, developed by PB Diagnostics (a
venture between Polaroi’d and Behring Diagnostics), two
different devices are used: one for a film technology, the
other for Elisa processes [7]. In the Elisa device,
antibodies are fixed in a glass-fibre support and the
specimen is delivered onto it. Then the conjugate and
washing solutions are delivered and diffused through the
glass-fibre matrix. In the other device, a film technology
is used. The basic principle is a competition between the
antigen and a fluorescent conjugate towards antibodies
fixed in a ’signal layer’.
The film is composed of different layers:
(1) The undiluted sample is applied in the spreader, then
it hydrates the layer.
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Figure 2. Multilayer structure and test procedure.
Multilayer structure: Ag-F complex between monoclonal antibody and hapten-Jluorescer conjugate. Test procedure: (2a) sample
rehydrates layers, antigen (Ag) diffuses towards signal layer; (2b) antigen displaces conjugate, free conjugate diffuses out ofsignal layer.
Reprintedfrom Grenner et al., Clinical Chemistry (1989).
(2) Big molecules are displaced and retained in the top-
coat layer.
(3) Sample antigen travels through the screen layer and
into the signal layer where it displaces labelled
antigen as seen before.
(4) The unbound antigen-fluorescent conjugate diffuses
freely and is distributed evenly in the layers. The red
pigment in the screen layer blocks excitation of the
label outside the signal layer. Fluorescence is
measured through the polyester fibre base.
Given the physical constraints of the solid phase sup-
ports, the incubation times and optical detection, this
approach is more adequate for short series. It does not
allow continuous loading of specimens and is unsuitable
for large volumes.
Discussion
With automated separation, heterogeneous immuno-
assays can easily be performed in large batches.
Targets for improved automation include:
Improved reagent stability in the System to about one
or two months.
(2) Multiparametric calibration solutions.
(3) Faster reactions which allow compact automation.
(4) Combination of homogeneous and heterogeneous
immunoassays in one system.
(5) Development of new solid phases like biosensors.
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